Researchers have investigated the epigenetic mechanisms associated with the CPT-1A promoter and found that butyrate, a dietary HDAC inhibitor, can protect against the ethanol-driven epigenetic deregulation of CPT-1A expression and reduce hepatic steatosis [58]. This evidence concerns the gene HDAC9 and Hepatic steatosis.